The Problems with Online Health Product Sales: How can Regulations be Improved?

IF 4 2区医学 Q1 PHARMACOLOGY & PHARMACY

Drug Safety Pub Date : 2024-06-01 Epub Date: 2024-03-14 DOI:10.1007/s40264-024-01414-8

Yi Jing Sng, Daryl Kwok, Eugene Goh, Annie Tan, Jessica Teo, Cheng Leng Chan

引用次数: 0

Abstract

With the rapid proliferation of online businesses, national authorities are facing challenges managing the online supply of illegal health products due to the anonymity of the internet, increasing number of global syndicates, new technologies, and inability to enforce against overseas sellers. This paper describes these challenges and the Health Sciences Authority's regulatory approaches to tackle the online sales of illegal health products. These include partnering with platform administrators to remove illegal online postings, leveraging technological tools and relevant legislation, empowering consumers to make informed decisions, and fostering closer collaborations across different jurisdictions to combat online pharmaceutical crimes.

查看原文本刊更多论文

网上保健品销售的问题：如何改进监管？

随着在线业务的迅速扩散，由于互联网的匿名性、全球集团数量的增加、新技术的出现以及无法对海外卖家进行执法，国家当局在管理非法保健品的在线供应方面面临着挑战。本文介绍了这些挑战以及卫生科学局应对网上非法保健品销售的监管方法。这些方法包括与平台管理员合作删除网上非法发布的信息、利用技术工具和相关立法、增强消费者作出知情决定的能力，以及促进不同司法管辖区之间的密切合作，以打击网上药品犯罪。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug Safety 医学-毒理学

CiteScore

7.60

自引率

7.10%

发文量

112

审稿时长

6-12 weeks

期刊介绍： Drug Safety is the official journal of the International Society of Pharmacovigilance. The journal includes: Overviews of contentious or emerging issues. Comprehensive narrative reviews that provide an authoritative source of information on epidemiology, clinical features, prevention and management of adverse effects of individual drugs and drug classes. In-depth benefit-risk assessment of adverse effect and efficacy data for a drug in a defined therapeutic area. Systematic reviews (with or without meta-analyses) that collate empirical evidence to answer a specific research question, using explicit, systematic methods as outlined by the PRISMA statement. Original research articles reporting the results of well-designed studies in disciplines such as pharmacoepidemiology, pharmacovigilance, pharmacology and toxicology, and pharmacogenomics. Editorials and commentaries on topical issues. Additional digital features (including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in Drug Safety Drugs may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand important medical advances.